AltPep
  • About
    • Our Company
    • Leadership
    • Board of Directors
    • Advisory Board
  • Our Approach
    • Our Approach
    • Product Pipeline
    • Scientific Publications
  • Team
  • News
    • News and Articles
    • Video Library
  • Careers
  • Contact
Select Page

AltPep Receives FDA Breakthrough Device Designation for SOBA-AD, A Simple Blood Test for the Detection of Alzheimer’s Disease

Mar 1, 2022

Breakthrough designation reinforces the significant potential of SOBA-AD assay to address the unmet need in Alzheimer’s Disease (AD) detection SOBA-AD assay is designed to selectively detect toxic oligomers that trigger a cascade of events associated with AD,...

AltPep Appoints Nancy Hill to Newly Created Position of Chief Product Officer

Feb 28, 2022

SEATTLE, WA – AltPep Corporation, a privately held biotechnology company developing early disease-modifying treatments and detection tools for amyloid diseases, today announced that accomplished executive Nancy Hill has assumed the newly created role of Chief Product...

Recent Posts

  • From Discovery to Design: Toward Early Detection and Treatment of Alzheimer’s Disease
  • Promising data from large Alzheimer’s study bodes well for this Seattle startup
  • Seattle startup aiming to detect, treat Alzheimer’s and Parkinson’s disease raises cash
  • Review: Amyloid-β Oligomers: Multiple Moving Targets
  • AltPep Receives FDA Breakthrough Device Designation for SOBA-AD, A Simple Blood Test for the Detection of Alzheimer’s Disease

Recent Comments

    • Home
    • Our Company
    • Our Approach
    • Careers
    • Contact
    • Linkedin
    • Twitter
    AltPep Corporation | 100 Northeast Northlake Way | Seattle, WA 98105